Poll Results On Longevity Peptides · BioOptimization Collective

Poll Results On Longevity Peptides

Mots-C received the most votes. Then #2 was Epitalon. #3 GHK-CU and #4 SS-31.

Most people accept aging as inevitable. The science increasingly does not.

What we call aging is a measurable cascade of cellular events. Mitochondrial decline. Telomere shortening. Collagen breakdown. Chronic inflammation that never fully resolves. These are not mysteries. They are addressable biological processes. And four compounds in the current research literature are targeting each one of them directly.

MOTS-c — Your Mitochondria Have a Longevity Signal. Here Is How to Restore It.

Identified in 2015 by researchers at USC and published in Cell, MOTS-c is encoded directly in mitochondrial DNA and activates AMPK — the same metabolic switch triggered by fasting and exercise. Published research shows improved insulin sensitivity, enhanced fat oxidation, and increased endurance in study models. A 2019 study confirmed MOTS-c levels decline significantly with age in humans, correlating directly with metabolic dysfunction and reduced physical capacity.

This is not a synthetic compound mimicking a natural process. It is the natural process itself, restored.

Epitalon — The Only Compound Shown to Activate Telomerase in Human Cells

Every cell division shortens your telomeres. When they get short enough cells stop dividing and begin secreting inflammatory signals that accelerate aging in surrounding tissue. That process is called cellular senescence and it is one of the primary drivers of age-related disease.

Epitalon, developed by Dr. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, has demonstrated telomerase activation in human somatic cells in peer-reviewed research published in Neoplasma. It has also shown restoration of melatonin rhythms, improved immune function, and in long-term studies a statistically significant extension of lifespan. Over 35 years of research and more than 100 published studies back this compound. That is not a claim. That is a track record.

GHK-Cu — 4,000 Genes. One Tripeptide.

GHK-Cu is a naturally occurring copper-binding tripeptide first identified in human plasma in 1973. Levels drop from roughly 200ng/mL at age 20 to under 80ng/mL by age 60. That decline tracks directly with reduced tissue repair, increased inflammation, and degraded wound healing.

Research by Dr. Loren Pickart — who has studied GHK-Cu for over four decades — shows it activates more than 4,000 human genes involved in tissue repair, collagen and elastin synthesis, anti-inflammatory response, and nerve regeneration. A 2012 gene expression analysis concluded it essentially resets tissue to a younger repair state.

The science is not new. The awareness of it is.

SS-31 — The Mitochondrial Compound With Human Clinical Trial Data

SS-31 targets cardiolipin on the inner mitochondrial membrane — the structure responsible for energy production efficiency. When cardiolipin degrades, mitochondrial output drops and oxidative stress accumulates, accelerating cellular aging across every tissue in the body.

SS-31 has been studied in human clinical trials for heart failure published in JACC Heart Failure, showing improved mitochondrial function and exercise capacity. Additional research demonstrates protective effects in neurodegeneration, renal ischemia, and age-related muscle decline. It is the only compound in this group to reach Phase 2 human clinical trials — giving it one of the strongest safety and mechanism profiles of any longevity peptide currently available.

Why These Four Together

Each compound targets a distinct mechanism. MOTS-c restores metabolic signaling. SS-31 protects mitochondrial structure. Epitalon addresses cellular aging at the telomere and pineal level. GHK-Cu handles structural repair, collagen integrity, and systemic inflammation.

No single compound covers all four. Together they do.

Aging is not one problem. It is a cascade of cellular events happening simultaneously across multiple systems. The protocols that produce real results address multiple points in that cascade at the same time.

The research exists. The compounds exist. The only question is how long you are willing to wait for mainstream medicine to catch up.

7 comments

Poll Results On Longevity Peptides